Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

INSPRA Film-coated tablet (2017)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

INSPRA 25 mg film-coated tablets.

Qualitative and quantitative composition

Each tablet contains 25 mg of eplerenone. Excipients with known effect: Each 25 mg tablet contains 35.7 mg of lactose monohydrate (see section 4.4). For the full list of excipients see section 6.1.

Pharmaceutical form

Film-coated tablet. 25 mg tablet: yellow tablet with stylized Pfizer on one side of tablet, NSR over "25"on the other side of tablet.

Therapeutic indications

Eplerenone is indicated: In addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular (CV) mortality and morbidity in stable patients with left ventricular dysfunction ...

Posology and method of administration

Posology For the individual adjustment of dose, the strengths of 25 mg and 50 mg are available. The maximum dose regimen is 50 mg daily. For post-MI heart failure patients The recommended maintenance dose ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with serum potassium level >5.0 mmol/L at initiation. Patients with severe renal insufficiency (eGFR ...

Special warnings and precautions for use

Hyperkalaemia: Consistent with its mechanism of action, hyperkalaemia may occur with eplerenone. Serum potassium levels should be monitored in all patients at initiation of treatment and with a change ...

Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions Potassium-sparing diuretics and potassium supplements Due to increased risk of hyperkalaemia, eplerenone should not be administered to patients receiving other potassium-sparing ...

Fertility, pregnancy and lactation

Pregnancy There are no adequate data on the use of eplerenone in pregnant women. Animal studies did not indicate direct or indirect adverse effects with respect to pregnancy, embryofoetal development, ...

Effects on ability to drive and use machines

No studies on the effect of eplerenone on the ability to drive or use machines have been performed. Eplerenone does not cause drowsiness or impairment of cognitive function but when driving vehicles or ...

Undesirable effects

In two studies (EPHESUS and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure [EMPHASIS-HF]), the overall incidence of adverse events reported with eplerenone was similar ...

Overdose

No cases of adverse events associated with overdose of eplerenone in humans have been reported. The most likely manifestation of human overdose would be anticipated to be hypotension or hyperkalaemia. ...

Pharmacodynamic properties

Pharmacotherapeutic group: aldosterone antagonists ATC code: C03DA04 Mechanism of action Eplerenone has relative selectivity in binding to recombinant human mineralocorticoid receptors compared to its ...

Pharmacokinetic properties

Absorption The absolute bioavailability of eplerenone is 69% following administration of a 100 mg oral tablet. Maximum plasma concentrations are reached after approximately 1.5 to 2 hours. Both peak plasma ...

Preclinical safety data

Preclinical studies of safety pharmacology, genotoxicity, carcinogenic potential and reproductive toxicity revealed no special hazard for humans. In repeated dose toxicity studies, prostate atrophy was ...

List of excipients

Tablet core: Lactose monohydrate Microcrystalline cellulose (E460) Croscarmellose sodium (E468) Hypromellose (E464) Sodium laurilsulfate Talc (E553b) Magnesium stearate (E470b) Tablet coating: Opadry yellow: ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

No special precautions for storage.

Nature and contents of container

Opaque PVC/Al blisters containing 10, 20, 28, 30, 50, 90, 100 or 200 tablets. Opaque PVC/Al perforated unit dose blisters containing 10 1, 20 1, 30 1, 50 1, 90 1, 100 1 or 200 1 (10 packs of 20 ...

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Marketing authorization number(s)

PL 00057/0615

Date of first authorization / renewal of the authorization

21/09/2004

Date of revision of the text

05/2017

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: